" Our partnerships with both NGS & TGS technology giants have facilitated the world’s most comprehensive populations genomics initiative, enabling us to provide cost-effective, high-accuracy sequencing at scale " : Ashish Koshy

28 June 2022 | Tuesday | News

BioPharma APAC, In an interaction with Ashish Koshy, CEO of G42 Healthcare
Ashish Koshy, CEO of G42 Healthcare

Ashish Koshy, CEO of G42 Healthcare


What are the major plans in store for G42 Healthcare? Any new segments to be explored?


  • G42 Healthcare is transforming the traditional healthcare ecosystem by harnessing data and advanced medical technologies. 
  • Our team of world-class doctors, scientists, and researchers are focused on leveraging our robust R&D capabilities encompassing genomics, imaging and diagnostics, and digitization programs to support the health of future generations by unlocking the potential of personalized and preventative care.
  • Our best-in-class lab services, novel omics technologies and biobanking powered cutting-edge research, and regional technology-enabled clinical research support governments, healthcare stakeholders, pharma companies, and technology first entities. 
  • Among our major plans we have genomics and sequencing research as a service, clinical genomics, microbiome sequencing, biobanking, access to electronic health data as a service, RWD/E analytics, decentralized clinical trials, AI-assisted CRO offerings, including drug discovery – and we are keen to collaborate with forces of change who share the common vision of better healthcare solutions with us. 
  • Our partnerships with both NGS & TGS technology giants have facilitated the world’s most comprehensive populations genomics initiative, enabling us to provide cost-effective, high-accuracy sequencing at scale. 
  • Our solutions lie at the crossroad between omics, science, data, advanced analytics, clinical research, healthcare, AI and business, which promises to transform conventional healthcare.
  • We are just back from the Bio International Convention 2022 in San Diego meeting significant players in global bio-innovation, connecting with scientists, innovators, investors, and enterprises at the first-ever AbuDhabi pavilion, and sharing insights to maximize international partnerships and alliances.
  • This will help further our goal of developing the right solutions that will ultimately lead to unlocking the full potential of personalized and preventative healthcare

How do you plan to enhance your growth within the APAC region?


We are always looking for new ways to grow our business strategically and I can say that APAC is very much on our radar. 

  • G42 Healthcare’s network of strategic global partners enables us to work on transforming healthcare worldwide. We’re always looking for new national and international opportunities to grow and scale our services. 
  • Partnerships are crucial to driving progress and allowing us to thrive. At G42 Healthcare, we have prioritized public-private partnerships and collaborated with government and private entities, pharma companies, tech entities, and academic institutions in the UAE and beyond. 
  • Our partnerships have constantly fueled our vision and helped fast-track the advancement of sustainable healthcare solutions in the UAE and beyond. 
  • We plan to approach our growth within the APAC region with the same ambition and enthusiasm. 

How is G42 Healthcare contributing to this fight against COVID-19?


  • Early in 2020, as humanity faced its worst healthcare crisis ever, we leveraged our AI and cloud computing expertise to facilitate the 4Humanity clinical trials, the world’s first phase III trials of inactivated vaccine against COVID-19 and set up Biogenix Labs, UAE’s first COVID-19 accredited large-scale throughput diagnostic laboratory.
  • Biogenix Labs – Omics Centre of Excellence has been instrumental in keeping communities safe and authorities informed via novel variant genome sequencing. The teams have supported decision-makers with quick, effective, and accurate analysis, thereby minimizing the risk of potential outbreaks. The emergence of new variants has demonstrated importance of continuous surveillance of infectious diseases and genomic epidemiology played a critical role in the successful control and prevention of the COVID-19 pandemic globally.
  • Leveraging technology, the lab facilitated the Back-to-School program for children, besides contributing to the lifting of travel restrictions by providing COVID-19 testing services for the IATA Travel Pass.
  • We have also facilitated research into new vaccines and drug therapies and are working on a Wastewater Lab to issue early warnings to prevent the spread of infectious diseases and curb adverse effects on the environment.

What will be the impact of this pandemic on the global economy? How is G42 preparing itself?


  • We can all recognize that the global economy has been and is still continuing to be impacted by the COVID-19 pandemic.
  • Its spread has left national economies and businesses counting the costs, as governments have struggled with new lockdown measures to tackle the spread of the virus.
  • The pandemic has taught us to harness technology more aggressively as it can play a crucial role in saving lives and fostering economic resilience. By championing technology, we can accelerate innovation and emphasize prevention
  • The pandemic has also taught us that we are stronger together. Partnerships and collaborations that allow us to unlock the healthcare industry's full potential are critical.  
  • We believe that the future of healthcare is preventive, predictive, and precision-oriented. Our AI-powered tools can assist medical professionals and researchers in understanding more about the different factors in our lives that influence our health. Ten years from now, we envision healthcare systems able to anticipate better, quicker and more accurate results. 
  • Our goal is to move from sick care to healthcare and grow beyond humans to industrial genomics, backed by innovative thinking and cutting-edge technology. 
  • We do this by harnessing big data and leveraging our cloud computing, AI platforms, and advanced medical technologies to unlock the potential of personalized and preventive care, transforming the traditional healthcare ecosystem. 
  • This will allow us to position ourselves at the forefront of diagnostics, omics, digital health, and therapeutics.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in